Context Although a number of studies have demonstrated the importance of constitutively
active androgen receptor variants (AR-Vs) in prostate cancer, questions still remain about …

While there are myriad mechanisms of primary and acquired resistance to conventional and
next-generation hormonal therapies in prostate cancer, the potential role of androgen …

Background The androgen receptor (AR) is a key prostate cancer drug target. Suppression
of AR signaling mediated by the full-length AR (AR-FL) is the therapeutic goal of all existing …

Abstract Background Approximately 10–30% of men with mCRPC will test positive for AR-V7
using one of two analytically and clinically validated circulating tumor cell (CTC)-based …

As prostate cancer (PCa) progresses to the lethal castration resistant and metastatic form,
genetic and epigenetic adaptation, clonal selection, and evolution of the tumor …

Androgen receptor splice variants (AR-Vs)—which are expressed in castration-resistant
prostate cancer (CRPC) cell lines and clinical samples—lack the C-terminal ligand-binding …

Opinion statement Metastatic castration-resistant prostate cancer (mCRPC) currently
benefits from a wealth of treatment options, yet still remains lethal in the vast majority of …

Simple Summary Androgen receptor splice variants (AR-Vs) play an important role in
prostate cancer progression, especially as a putative resistance mechanism against AR …

Many therapeutic options are now available for men with metastatic castration-resistant
prostate cancer (mCRPC), including next-generation androgen receptor axis-targeted …

The androgen receptor (AR) plays a key role in progression to metastatic castration-resistant
prostate cancer (mCRPC). Despite the recent progress in targeting persistent AR activity …